← All indications
Esophageal Diseases
Pathological processes in the ESOPHAGUS.
Subtype terms (11)
More specific conditions that are subtypes of Esophageal Diseases in the MeSH hierarchy.
- Barrett Esophagus
39 drugs (26 approved, 13 experimental)
- Deglutition Disorders
66 drugs (45 approved, 21 experimental)
- Diverticulosis, Esophageal
- Esophageal and Gastric Varices
72 drugs (47 approved, 25 experimental)
- Esophageal Atresia
5 drugs approved
- Esophageal Cyst
- Esophageal Fistula
1 drug experimental
- Esophageal Neoplasms
750 drugs (232 approved, 518 experimental)
- Esophageal Perforation
- Esophageal Stenosis
9 drugs (8 approved, 1 experimental)
- Esophagitis
39 drugs (23 approved, 16 experimental)
Drugs by status
Phase 4 trials (6)
Phase 3 trials (9)
Phase 2 trials (25)
- abemaciclib
- anlotinib
- paclitaxel
- naloxegol
- rimabotulinumtoxinB
- nimotuzumab
- azd1386
- prucalopride succinate
- endostatin
- bevacizumab
- itraconazole
- cabazitaxel
- esophageal cancer peptide specific ctl
- gimeracil
- oteracil
- superoxide dismutase
- erlotinib
- cisplatin
- tegafur
- sargramostim
- oncoxin-viusid
- camrelizumab
- sintilimab
- savolitinib
- tqb2450
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (7)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (2)